We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Refinitiv and Factset).
We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.
Published reports can be obtained by searching our Research Library below, or directly from our Featured Companies page.
HUTCHMED
Looking ahead to the next chapterFutura Medical
Innovating, and adapting, in a new product categoryANGLE
Assays complete for AstraZeneca; utility of HER2 demoedHUTCHMED
Profitability milestone achieved ahead of scheduleAvacta
Executing steadily on therapeutics focused strategyOxford BioDynamics
Seeking deals to enhance EpiSwitch revenue potentialArecor Therapeutics
AT278 co-development deal in advanced discussionsANGLE
A fuller picture from dual CTC-DNA and ctDNA analysisFutura Medical
FY25 revenues to be materially below expectationsScancell
H125 reaffirms funds are sufficient to deliver key data